Close Menu

Drug companies are setting up R&D arms in China, staffing them with local scientists or expat-trained Chinese scientists, to encourage innovative drug research in the country. The GSK R&D center in Shanghai will have a first-year operating budget of $40 million, and AstraZeneca’s Innovation Center China was set up in June 2006 to develop drugs for gastric tract and liver cancers that are prevalent in China.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.